Evgen Pharma Share Discussion Threads

[mesquida] 07/1/2021 15:25

Stock price seems to have just woken up !

[bumpa33] 07/1/2021 15:15

Value will out in the end...

[moneymunch] 07/1/2021 11:32

Lol, yep it's taking a lot longer than first anticipated, but hopefully a flow of good news will drop like dominoes from now on in....tick bloody tock!!! :-)))

[bumpa33] 07/1/2021 09:23

thanks mm, i’m more likely to die of boredom watching this one. Thank heavens for day/swing trading.

[moneymunch] 06/1/2021 22:15

Sorry to hear of anything that's affected you personally Bumpa...satisfactory treatments are few and far between and those that were thought to have the greatest potential have failed or therapeutic benefit results have been ambiguous at the very least, SFX-01's Covid-19 potentisl has been overlooked and almost disregarded, maybe because its focus is on ARDS, and so any positive indications starting with DSMB's assessment on the first 100 patients recruited , should be very well received. Gl and stay safe and well. :-)

[bumpa33] 06/1/2021 21:29

6277 well mm, that was my understanding of what’s really spooking govts etc and from a mix of sources and personal experience, I fully understand why.

And yes, partly in light of this - treatments for me are where it’s really at.

[bumpa33] 06/1/2021 21:27

Interesting goings on in Washington tonight. The yanks really are nutters. Markets starting to look well overheated but one tech commentator I follow has the S&P nailed at 4500 before the whole thing implodes sometime in 2021.

[moneymunch] 06/1/2021 21:24

Yep, it looks pretty grim and scary reading Bumpa, and something I wasn't really aware of until I found the article earlier...and certainly not made public or similar data published in the UK as far as I know....which must add value to any treatment (s) that are finally endorsed...there ain't many!!!??? :-(

[bumpa33] 06/1/2021 21:11

this is what they’re really worried about, not so much the deaths...

[bumpa33] 06/1/2021 21:09

mm - 6274 - what was I saying the other day...?

[moneymunch] 06/1/2021 18:02

Nearly a third of COVID-19 survivors readmitted to hospital within 60 days


6 January, 2021  

Although much has been written about the extent to which patients with COVID-19 have been either hospitalised or died, far less attention has been paid to what happens to those who have been successfully treated and discharged from hospital.

.....

Findings

From the initial 2179 index hospitalisations due to COVID-19, a total of 1775 (81.5%) survived to be discharged. Within 60 days of discharge, 479 (27%) of these discharged patients were re-admitted to hospital and 162 (9.1%) died. The most common reasons for re-admission was COVID-19 (30.2%), sepsis (8.5%), pneumonia (3.1%) and heart failure (3.1%). Moreover, during re-admission, 22.6% required intensive care treatment, 7.1% were mechanically ventilated and 7.9% received vasopressors. Compared with patients hospitalised with either non-COVID pneumonia (1799) or heart failure (3505), COVID-19 patients actually had lower rates of readmission within 60 days but higher rates within 10 days of discharge.

The authors concluded by noting that while much surveillance is focused on inpatient mortality from COVID-19, this data substantially underestimates the burden of the disease.

[toffeeman] 06/1/2021 16:35

>> nothing, just to free up the board

[andymunchkin] 06/1/2021 15:02

Iam havingBrocolliJuice fullOf selfiLorraine

[andymunchkin] 06/1/2021 08:25

moneymunch8 Feb '18 - 14:54 - 84 of 1015
0 2 0. Msys
4p plus soon...you know I'm right...ha ha ha:-)
———;——̵2;
PriceToday. .28p wtf WhereIs theRampngCnt?????

[moneymunch] 05/1/2021 12:50

One would think that sooner or later , a Major will make a move for one of SFX-01's disease targets. Gla ;-)

October 26, 2020

News briefing: AstraZeneca follows Amgen down KRAS/SHP2 combo path;

Revolution Medicines is adding AstraZeneca to its roster of clinical collaborators, lending its lead drug, RMC-4630, for a study pairing it with the pharma giant’s KRAS G12C program.

AstraZeneca will sponsor and conduct the study once its now preclinical drug is ready for human studies, an arrangement similar to the deal Revolution has with Amgen on sotorasib.

“Drug combinations are likely to be critical for defeating inherent drug resistance mechanisms exploited by RAS-addicted cancers,” CEO Mark Goldsmith said in a statement.


An allosteric SHP2 inhibitor, RMC-4630 attracted Sanofi for a partnership that involved $50 million upfront, 80% of the R&D cost, and a swath of milestones adding up to $520 million. Revolution is also working on a pipeline — from its buyout of Warp Drive Bio — of drugs that directly inhibit oncogenic RAS(ON) variants, including KRASG12C(ON) and KRASG12D(ON).

[moneymunch] 05/1/2021 12:08

and another..;-)

December 21, 2020

Financing

China

Months af­ter strik­ing SHP2 deal with Ab­b­Vie, Ja­co­bio pulls in $174M+ from Hong Kong IPO


The sea­soned crew at Ja­co­bio has raised $174.1 mil­lion on its HKEX de­but, fu­elling a pipeline an­chored by two Ab­b­Vie-part­nered al­losteric SHP2 in­hibitors.

..............


AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors

News provided by
AbbVie

Jun 01, 2020, 01:00 ET

Share this article

NORTH CHICAGO, Ill. and BEIJING, June 1, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company, today announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells.

SHP2 is an important protein mediator of cellular signaling through RAS/MAP kinase pathway. Many tumors have genetic mutations, driving abnormal cancer cell growth which relies on SHP2 activity. SHP2 also plays a key role to control cytokine production and immune cell response. Therefore, inhibition of SHP2 is believed to have dual effects by potentially reducing cancer cell growth and modulating immune responses to generate anti-tumor activities. Jacobio's early clinical stage SHP2 assets, JAB-3068 and JAB-3312, are oral small molecules designed to specifically inhibit SHP2 activity.

"Identifying promising new targeted approaches for solid tumor patients is a high priority for us," said Mohit Trikha, Ph.D., vice president and head, early development oncology and Bay Area site head, AbbVie. "Jacobio's SHP2 program has the potential to treat cancer patients across many tumor types. By targeting a key node in both cancer and immune cell signaling pathways, SHP2 inhibition, both as a monotherapy and potentially in combination with other agents, may rapidly advance new treatment options for cancer patients."

"We are excited to expand our efforts in global development of delivering breakthrough innovation to not just Chinese, but global patients with cancer," said Yinxiang Wang, Ph.D., CEO and Chairman, Jacobio. "We look forward to a productive collaboration with AbbVie focused on rapidly advancing this novel SHP2 first-in-class therapy as a new approach for multiple cancer types. I am confident that this partnership will strengthen our R&D capabilities and ultimately bring benefits to cancer patients."

Under the terms of the agreement, AbbVie will be granted an exclusive license to the SHP2 portfolio. Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 with AbbVie covering R&D expenses. Upon completion, AbbVie will assume global development and commercialization responsibilities. Jacobio has an option, exercisable before the initiation of registrational trials, to exclusively develop and commercialize the SHP2 program in mainland China, Hong Kong, and Macau. Financial terms were not disclosed and the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

[moneymunch] 05/1/2021 12:03

A recent example of the potential value of SFX-01's SHP2 inhibition. Gla ;-)



Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971

December 14, 2020

Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors

Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25 million in near-term payments and $695 million in additional potential milestones,
plus royalties on global net product sales

[moneymunch] 05/1/2021 11:31

Great prospects and undoubted transformational upside potential peanut, we just need some good positive solid material news to get the market excited. Any early news on the assessment of the first 100 patients and the green light from the Data and Safety Monitoring Board (DSMB) on the current Covid-19/ARDS patient trial should add significant market interest and substantial value, and news on SFX-01's breast cancer clinical work towards its phase2b trial and the rest of the pipeline under evaluation could be close , as well as disclosure on the following potential game changer.....Multiple shots on Multiple disease targets......Sooner or later this is going to move BIG with any luck....;-)

10/12/20

"I look forward to updating the market and our shareholders on our next cancer indication in due course, where preliminary pre-clinical data look compelling. We continue to demonstrate the huge potential of our pipeline and are excited for the future progression of this."

Solid tumour oncology target

In a collaboration which will be disclosed when patent filings and a scientific paper have been prepared, strong preclinical data has been generated when SFX-01 was evaluated in a model of a cancer with very poor life expectancy, and for which current treatments are limited.

In particular, in vitro studies with patient-derived cell lines showed dose-dependent reduction in proliferation and migration. Further, in vivo orthotopic xenograft models, treatment with SFX-01 increased disease-free survival and lengthened tumour progression times, an effect that is synergistic with radiotherapy.